SOMAÍ Pharmaceuticals is excited to announce a major milestone in its journey towards revolutionizing the cannabis-based therapeutics industry, having successfully raised €9,200,000 in funding. As a leading EU-GMP European vertically integrated Multi-Country Operator (MCO) company, SOMAÍ continues to enhance its global footprint by harnessing its state-of-the-art manufacturing facility and advanced indoor cultivation operations in Lisbon, Portugal, to meet the rising demand for innovative, EU GMP-certified cannabinoid-containing pharmaceuticals. This significant capital raise will empower SOMAÍ to expand its already robust distribution network across key global markets and further strengthen existing strategic partnerships and acquisitions, marking a transformative phase in its mission to build a leading global brand.
The funding will specifically be directed toward accelerating the development and deployment of SOMAÍ's extensive pipeline of innovative cannabis-based therapeutics. This reinvestment will support research and development efforts, infrastructure upgrades, and market expansion initiatives, ensuring that SOMAÍ stays at the forefront of delivering high-quality, natural cannabis medicine that empowers individuals to lead healthier, more balanced lives. With a comprehensive portfolio developed under strict EU GMP standards, SOMAÍ is uniquely positioned to address the diverse needs of a fast-growing global market, offering solutions that are as safe as they are effective.
This capital infusion not only reaffirms the confidence that investors have in SOMAÍ’s vision and capabilities but also reflects the company's commitment to innovation and excellence. As SOMAÍ Pharmaceuticals continues to pave the way in the rapidly evolving medical cannabis landscape, it remains dedicated to advancing sustainable health solutions that paves the road to a future where wellness is enhanced by nature’s own remedies.
